Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
BackgroundInfiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced H...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1474442/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846091433345286144 |
|---|---|
| author | Zizhuo Wang Zizhuo Wang Zizhuo Wang Songlin Song Songlin Song Songlin Song Lijie Zhang Lijie Zhang Lijie Zhang Tingting Yang Tingting Yang Tingting Yang Wei Yao Wei Yao Wei Yao Bin Liang Bin Liang Bin Liang |
| author_facet | Zizhuo Wang Zizhuo Wang Zizhuo Wang Songlin Song Songlin Song Songlin Song Lijie Zhang Lijie Zhang Lijie Zhang Tingting Yang Tingting Yang Tingting Yang Wei Yao Wei Yao Wei Yao Bin Liang Bin Liang Bin Liang |
| author_sort | Zizhuo Wang |
| collection | DOAJ |
| description | BackgroundInfiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced HCC, but its role in advanced infiltrative HCC is unclear. This study aims to investigate the efficacy and safety of HAIC combined with ICIs and MTTs in the treatment of advanced infiltrative HCC.MethodsPatients with infiltrative HCC initially treated with HAIC plus ICIs and MTTs were consecutively included at our institution from November 2021 to June 2023. The efficacy evaluation included tumor response, time to response (TTR), duration of response (DOR), progression-free survival (PFS) per RECIST 1.1, and patient survival. Adverse events (AEs) were recorded for safety evaluation.ResultsA total of 27 patients were included and the median follow-up was 15.8 months (range, 4.3–25.9). The best objective response rate (ORR) and disease control rate (DCR) were 70.4% and 88.9%, respectively. The median TTR was 2.8 months (95% confidence interval [CI], 2.6–3.0) and the median DOR was 7.9 months (95% CI, 3.2–12.5). The median PFS was 7.5 months (95% CI, 4.2–10.7), and the median overall survival (OS) was 16.8 months (95% CI, 14.0–19.6), with a 1-year OS rate of 74.1%. No cases of grade 4 or 5 treatment-related adverse events (TRAEs) were observed in this study. Grade 3 TRAEs occurred in 17/27 (63.0%) patients, and the predominant grade 3 treatment-related adverse events were lymphocyte count decreased (18.5%) and neutrophil count decreased (14.8%).ConclusionsThe combination of HAIC plus ICIs and MTTs demonstrated encouraging outcomes and manageable safety concerns for infiltrative HCC. |
| format | Article |
| id | doaj-art-5bdc7c2dd7134bb68de8a4cfe26ce4d2 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-5bdc7c2dd7134bb68de8a4cfe26ce4d22025-01-10T06:10:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14744421474442Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experienceZizhuo Wang0Zizhuo Wang1Zizhuo Wang2Songlin Song3Songlin Song4Songlin Song5Lijie Zhang6Lijie Zhang7Lijie Zhang8Tingting Yang9Tingting Yang10Tingting Yang11Wei Yao12Wei Yao13Wei Yao14Bin Liang15Bin Liang16Bin Liang17Department of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaBackgroundInfiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced HCC, but its role in advanced infiltrative HCC is unclear. This study aims to investigate the efficacy and safety of HAIC combined with ICIs and MTTs in the treatment of advanced infiltrative HCC.MethodsPatients with infiltrative HCC initially treated with HAIC plus ICIs and MTTs were consecutively included at our institution from November 2021 to June 2023. The efficacy evaluation included tumor response, time to response (TTR), duration of response (DOR), progression-free survival (PFS) per RECIST 1.1, and patient survival. Adverse events (AEs) were recorded for safety evaluation.ResultsA total of 27 patients were included and the median follow-up was 15.8 months (range, 4.3–25.9). The best objective response rate (ORR) and disease control rate (DCR) were 70.4% and 88.9%, respectively. The median TTR was 2.8 months (95% confidence interval [CI], 2.6–3.0) and the median DOR was 7.9 months (95% CI, 3.2–12.5). The median PFS was 7.5 months (95% CI, 4.2–10.7), and the median overall survival (OS) was 16.8 months (95% CI, 14.0–19.6), with a 1-year OS rate of 74.1%. No cases of grade 4 or 5 treatment-related adverse events (TRAEs) were observed in this study. Grade 3 TRAEs occurred in 17/27 (63.0%) patients, and the predominant grade 3 treatment-related adverse events were lymphocyte count decreased (18.5%) and neutrophil count decreased (14.8%).ConclusionsThe combination of HAIC plus ICIs and MTTs demonstrated encouraging outcomes and manageable safety concerns for infiltrative HCC.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1474442/fullinfiltrative hepatocellular carcinomahepatocellular carcinomahepatic arterial infusionimmunotherapymolecular targeted therapy |
| spellingShingle | Zizhuo Wang Zizhuo Wang Zizhuo Wang Songlin Song Songlin Song Songlin Song Lijie Zhang Lijie Zhang Lijie Zhang Tingting Yang Tingting Yang Tingting Yang Wei Yao Wei Yao Wei Yao Bin Liang Bin Liang Bin Liang Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience Frontiers in Immunology infiltrative hepatocellular carcinoma hepatocellular carcinoma hepatic arterial infusion immunotherapy molecular targeted therapy |
| title | Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience |
| title_full | Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience |
| title_fullStr | Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience |
| title_full_unstemmed | Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience |
| title_short | Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience |
| title_sort | hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma a single center experience |
| topic | infiltrative hepatocellular carcinoma hepatocellular carcinoma hepatic arterial infusion immunotherapy molecular targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1474442/full |
| work_keys_str_mv | AT zizhuowang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT zizhuowang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT zizhuowang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT songlinsong hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT songlinsong hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT songlinsong hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT lijiezhang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT lijiezhang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT lijiezhang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT tingtingyang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT tingtingyang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT tingtingyang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT weiyao hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT weiyao hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT weiyao hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT binliang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT binliang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience AT binliang hepaticarterialinfusionchemotherapycombinedwithimmunecheckpointinhibitorsandmoleculartargetedtherapiesforadvancedinfiltrativehepatocellularcarcinomaasinglecenterexperience |